Scientists shut down pump action to break breast cancer cells' drug resistance

Sep 28, 2011

(PhysOrg.com) -- Breast cancer cells that mutate to resist drug treatment survive by establishing tiny pumps on their surface that reject the drugs as they penetrate the cell membrane – making the cancer insensitive to chemotherapy drugs even after repeated use.

Researchers have found a new way to break that resistance and shut off the pumps by genetically altering those to forcibly activate a heat-shock called Hsp27. This protein regulates several others, including the protein that sets up the pumps that turn away the chemotherapeutics.

In experiments, the common chemotherapy drug Doxorubicin killed about 50 percent more drug-resistant breast cancer in which Hsp27 had been activated than it did in normal drug-resistant cells.

Though these results have been shown only in cell cultures in a lab, they suggest that there someday could be a clinical way to use this approach to reverse the drug resistance that can develop in breast . The study was conducted in MCF-7/adr breast cancer cells, which resist the effects of Doxorubicin.

"These cells are actually resistant to multiple drugs, so the resistance will be there even if clinicians move on to other chemotherapeutics. It's a serious issue," said Govindasamy Ilangovan, associate professor of internal medicine at Ohio State University and senior author of the research. "The plausible way to circumvent this effect is to suppress the resistance by shutting down the drug extrusion pump using molecular approaches. That is what we're trying to address."

The study appears in the Sept. 23 issue of the Journal of Biological Chemistry.

The researchers analyzed proteins in regular breast cancer cells from the MCF-7 cell line as well as multidrug resistant cells from the same line. The normal breast cancer cells are known to be sensitive to chemotherapy drugs.

The tests indicated that the normal cells contained HSF-1, the transcription factor that activates the heat shock protein Hsp27. However, in the drug-resistant cells, HSF-1 was extremely low and Hsp27 was present in only trace amounts.

Previous research has established that Hsp27 controls two other proteins, including the culprit protein that makes the cells drug resistant by establishing pumps to extrude chemotherapeutics out of cells. This pumping protein's level was clearly high in the drug-resistant cells, and nonexistent in the normal cells.

"The existence of this pump-action protein, called P-gp, is bad because it is removing the drugs from the cells. The cells do not even feel the presence of the drug in the system. We need to lower the amount of P-gp so that the drug stays in the cells to cause the intended damage. So we decided to model how to achieve this by forcibly bringing back the Hsp27," said Ilangovan, also an investigator in Ohio State's Davis Heart and Lung Research Institute.

In these experiments on cells, the researchers performed gene transfer using a viral vector to deliver the Hsp27 gene into the drug-resistant cells. As expected, after the addition of this gene the Hsp27 protein was abundantly induced and the drug-resistant protein p-gp went down in the cells.

"Then we tested the cells under this condition to determine whether we could sensitize these resistant cells to the drug," Ilangovan said.

After treatment with varying levels of Doxorubicin, about 50 percent more resistant cells in which Hsp27 had been forcefully activated died compared to normal drug-resistant cells. In addition, fluorescent staining of the cells showed that the expression of Hsp27 in these cells also caused them to absorb much more of the chemotherapy drug – a sign the drug was not being pumped away.

Additional experiments showed that these genetically altered cells died in the way they typically would in response to chemotherapy – by undergoing a programmed cell death process called apoptosis.

"We proved Doxorubicin does kill these cells in the way it is supposed to," Ilangovan said.

The findings represent a twist of sorts in molecular biology because heat-shock proteins typically are activated by stress. But in this case, the drug-resistant cells become reprogrammed over time – presumably, in response to the stress of being treated with drugs intended to kill them – and instead of being full of heat-shock protein activity, those stress-induced proteins are silenced.

"Because these proteins are involved, it looks at present like there could be a strong link between chronic stress and this drug-resistant mechanism evolving in the cells, but we need to carry out additional new studies to make any solid conclusion on chronic stress and drug resistance in cancer," Ilangovan said.

Translation of this technique in humans is years away, but would likely involve the delivery of the Hsp27 gene into drug-resistant cancer cells to induce activation of the Hsp27 protein, he said. The next step in this work involves refining the gene transfer process and demonstrating it in animal models.

Explore further: Four billion-year-old chemistry in cells today

More information: www.jbc.org/

Related Stories

Breast cancer cells outsmart the immune system and thrive

Feb 01, 2011

Scientists discovered a new way breast cancer cells dodge the immune system and promote tumor growth, providing a fresh treatment target in the fight against the disease. While comparable mechanisms to avoid the immune system ...

Double-Duty Nanoparticles Overcome Drug Resistance in Tumors

Jun 14, 2007

Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors ...

HOXB7 gene promotes tamoxifen resistance

Dec 11, 2010

Many postmenopausal women with early-stage breast cancers who initially respond well to tamoxifen become resistant to the drug over time and develop recurrent tumors. Johns Hopkins Kimmel Cancer Center researchers have found ...

Knocking Out Survival Protein Could Aid Leukemia Treatment

Apr 23, 2007

An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows. The findings suggest that a drug that can block this “survival protein” might on its ...

Recommended for you

Building the ideal rest stop for protons

10 hours ago

Where protons, or positive charges, decide to rest makes the difference between proceeding towards ammonia (NH3) production or not, according to scientists at Pacific Northwest National Laboratory (PNNL) and ...

Cagey material acts as alcohol factory

12 hours ago

Some chemical conversions are harder than others. Refining natural gas into an easy-to-transport, easy-to-store liquid alcohol has so far been a logistic and economic challenge. But now, a new material, designed ...

User comments : 0